Though Cigna’s reimbursement medical home model is still in its very early stages, Bhuvana Sagar, MD, national medical director of Cigna Healthcare, explained that discussing value in healthcare and getting back to smarter spending as well as better outcomes for patients should be the focus of all industry stakeholders.
Though Cigna’s reimbursement medical home model is still in its very early stages, Bhuvana Sagar, MD, national medical director of Cigna Healthcare, explained that discussing value in healthcare and getting back to smarter spending as well as better outcomes for patients should be the focus of all industry stakeholders.
Transcript slightly modified)
Will the information generated from the various value frameworks out there influence reimbursement decisions by Cigna?
Definitely, definitely. So what we’re trying to do is we’re trying to get as much data as possible and at this point with our reimbursement medical home models that we have in place—these have been there only for a short time, relatively a short time, probably about a year—we’re still trying to get data, we’re still trying to get experience with the program, providers are still getting used to it, customers are still trying to get used to it.
So once we have more information, we’re definitely going to look and see what works, what doesn’t work and where the greatest impact is going to be and go from there.
Why do you think we need to have the value discussion in healthcare today?
Well with rising healthcare costs and we can’t continue to ignore them at this point and we as a society need to do something to address the cost. You know, the different stakeholders need to be involved in the discussion and we’ve come to a point where we all understand that the fee-for-service system just seems to be adding a lot of that volume without necessarily affecting the quality of care.
So we want to go back to what’s important. We want to have smarter spending, better outcomes for our patients and overall better healthcare for our patients.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More